Torres Viviana, González-Ortega Guillermo, Suárez Antoni, Garrido Alicia, Cámara Ana, Compta Yaroslau, Valldeoriola Francesc
Parkinson's Disease and Movement Disorders Unit, Neurology Service, Institut de Neurociencies, Hospital Clínic of Barcelona, Catalonia, Spain.
Parkinson's Disease & Movement Disorders Unit, Neurology Service, Hospital Clínic I Universitari de Barcelona; IDIBAPS, CIBERNED (CB06/05/0018-ISCIII), ERN-RND, Institut Clínic de Neurociències (Maria de Maeztu Excellence Centre), Universitat de Barcelona. Barcelona, Catalonia, Spain; Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders: Clinical and Experimental Research; Department of Neurology, Hospital Clínic de Barcelona, Institut D'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Barcelona, Catalonia, Spain.
Clin Park Relat Disord. 2022 Jul 1;7:100150. doi: 10.1016/j.prdoa.2022.100150. eCollection 2022.
Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel (LCIG) is one of the primary therapies for improving advanced Parkinson's disease symptoms. Placement of the jejunal catheter through the abdominal wall for drug administration requires a percutaneous interventional procedure called percutaneous endoscopic gastrostomy (PEG). PEG is considered a safe and straightforward procedure, and it is performed very commonly in clinical practice. In the context of LCIG treatment, severe adverse events have been identified, such as intestinal bleeding and acute abdomen [1], but acute acalculous cholecystitis (AAC) has never been reported.
持续空肠输注左旋多巴-卡比多巴肠凝胶（LCIG）是改善晚期帕金森病症状的主要治疗方法之一。通过腹壁放置空肠导管进行药物给药需要一种称为经皮内镜下胃造口术（PEG）的经皮介入操作。PEG被认为是一种安全且简单的操作，在临床实践中非常常见。在LCIG治疗的背景下，已经发现了严重的不良事件，如肠道出血和急腹症[1]，但急性非结石性胆囊炎（AAC）从未被报道过。
